Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in very early treatment-naïve RRMS (AGNOS)
NCT05084638Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Jan 2022; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05084638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084638.